Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02632877

Efficacy of Pirfenidone Plus MODD in Diabetic Foot Ulcers

Efficacy of Pirfenidone Gel Combined With Modified Oxide Diallyl Disulfide (MODD) Versus Ketanserin for the Treatment of Diabetic Foot Ulcers

Sponsor: Cell Pharma

Conditions Diabetic Foot Ulcer

Interventions Ketanserin Pirfenidone with MODD

Updated 6 times since 2017 Last updated: Dec 14, 2015 Started: Jan 31, 2014 Primary completion: Nov 30, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02632877, this PHASE1/PHASE2 trial focuses on Diabetic Foot Ulcer and remains completed. Sponsored by Cell Pharma, it has been updated 6 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2019 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2019 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cell Pharma
University of Guadalajara

Data source: University of Guadalajara

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guadalajara, Mexico
• Zapopan, Mexico